Version July 2025
Tinea infection:
Tinea corporis/tinea cruris: Topical: Cream: Apply to affected and surrounding area(s) once daily until clinical resolution, typically 1 to 3 weeks (Ref).
Tinea pedis (labeled use)/tinea manuum (off-label use): Topical: Cream: Apply to affected and surrounding area(s) once daily until 1 week after clinical resolution, typically for 2 to 4 weeks total (Ref).
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
(For additional information see "Luliconazole: Pediatric drug information")
Tinea corporis (ringworm): Children ≥2 years and Adolescents: Topical: Apply to affected and surrounding area(s) once daily until clinical resolution; typically 1 week.
Tinea cruris (jock itch): Children ≥12 years and Adolescents: Topical: Apply to affected and surrounding area(s) once daily until clinical resolution; typically 1 week.
Tinea pedis (athlete's foot): Children ≥12 years and Adolescents: Topical: Apply to affected and surrounding area(s) once daily until clinical resolution; typically 2 weeks.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
<1%, postmarketing, and/or case reports: Application site reaction, cellulitis, contact dermatitis
There are no contraindications listed in the manufacturer's labeling.
Warnings/precautions:
• Appropriate use: For topical use only; not for oral, ophthalmic, or intravaginal use.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Cream, External:
Luzu: 1% (60 g) [contains benzyl alcohol, methylparaben, propylene glycol]
Generic: 1% (60 g)
Yes
Cream (Luliconazole External)
1% (per gram): $4.00
Cream (Luzu External)
1% (per gram): $9.84
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
For topical use only. Not for ophthalmic, oral, or intravaginal use. Apply to affected area and ~1 inch of immediate surrounding area(s). Wash hands following application.
Topical: For topical use only; not for ophthalmic, oral, or intravaginal use. Apply to affected area and ~1 inch of immediate surrounding area(s). Wash hands following application.
Fungal infections: Topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum and Epidermophyton floccosum.
Tinea manuum
Inhibits CYP2C19 (Weak);
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
CloBAZam: CYP2C19 Inhibitors (Weak) may increase serum concentration of CloBAZam. CYP2C19 Inhibitors (Weak) may increase active metabolite exposure of CloBAZam. Risk C: Monitor
Fosphenytoin-Phenytoin: CYP2C19 Inhibitors (Weak) may increase serum concentration of Fosphenytoin-Phenytoin. Risk C: Monitor
Mavacamten: CYP2C19 Inhibitors (Weak) may increase serum concentration of Mavacamten. Management: Start mavacamten at 5 mg/day if stable on a weak CYP2C19 inhibitor, and reduce the mavacamten dose by one dose level if initiating a weak CYP2C19 inhibitor. Avoid initiating weak CYP2C19 inhibitors in patients on mavacamten 2.5 mg/day. Risk D: Consider Therapy Modification
Adverse events were observed in some animal reproduction studies. Small amounts of luliconazole are absorbed systemically.
It is not known if luliconazole is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.
Azole antifungal that appears to inhibit ergosterol synthesis by inhibiting the enzyme lanosterol demethylase, resulting in decreased amounts of ergosterol and a corresponding accumulation of lanosterol.
Absorption: Small amounts may be absorbed following topical application.
Protein binding: >99%; to plasma proteins.
